Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: FDA Medical Device Regulations Experts: Legal, Economic, and Regulatory Affairs(?)

Council Members in this Study Group: 53

This study group may include professors, attorneys, former regulatory officers, and consultants knowledgeable on topics such as law and litigation issues, lobbying, policy and government, elections, antitrust, immigration, intellectual property, and legislation, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Stephen Bent, Partner & Co-Chair, Life Sciences, Foley & Lardner LLPStephen Bent
Partner & Co-Chair, Life Sciences
Foley & Lardner LLP

Stephen A. Bent is Partner and co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr. Bent specializes on the legal issues associated with biotechnology...


Thomas Saunders, Partner, Seyfarth Shaw LLPThomas Saunders
Partner
Seyfarth Shaw LLP

Thomas Saunders is a Partner at Seyfarth Shaw in Boston, Massachusetts, where he specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing matters and ANDA Paragraph IV...


2 recent news post(s)
Marc Scheineson, Partner & Chair, Food and Drug Practice, Alston & Bird LLPMarc Scheineson
Partner & Chair, Food and Drug Practice
Alston & Bird LLP

Marc Scheineson is a Partner with Alston & Bird where he heads the firm's Food and Drug Law Practice. He has practiced food and drug law, health care law and administrative law for over 20 years in national law firms and at the FDA. His practice focuses on determining the regulatory course of least...


Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
RIPENING INHIBITORS: ROSY FUTURE OR BRUISED FRUIT? | 12-21-2007
Analysis of: Current and Potential Commercial Applicationsof the Suppression of Ethylene Action by 1-MCP in Plants | www.rohmhaas.com
Author: Thomas Saunders, Partner, Seyfarth Shaw LLP

    Product shelf-life is a major economic concern for the agricultural industry.   The biological mechanism for regulating the ripening of fruits is mediated by ethylene.     Ethylene  management is addressed in three ways: 1) Ethylene...

Defending Knock-Offs: Head-to-head With Brand Names in Trademark, Copyright, and Internet Marketing | 03-01-2007
Analysis of: Defending Knock-Offs: Head-to-head With Brand Names in Trademark, Copyright, and Internet Marketing | www.iptoday.com
Author: Thomas Saunders, Partner, Seyfarth Shaw LLP

-Name Brands vs, Knock-Offs: Strategies and Counter-Strategies -Vulnerabilities of Name Brand Copyrights -Why the internet Knock-Off market will always exist

View All GLG News by members of this Study Group

Most Common Company Types:

  • Law Firm (general practice/large)
  • Law Firm (Boutique / Specialized)
  • Consultancy, Healthcare-Focused
  • Lobbying Firm
  • Advocacy Group or Issue Focused

Most Common Job Types:

  • Partner
  • Principal
  • Vice President
  • Director
  • Chief Executive Officer

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics